title: The past, present and future of transgenic bioreactors.
abstract: Hybrid genes can control the tissue-specific synthesis of human proteins in transgenic animals. Thus, it is now possible to produce proteins of biomedical value in the body fluids or cells of transgenic livestock. In fact, the first transgenically produced protein, antithrombin III, is now in clinical trials and others will soon follow.
authors.affiliation: J. Holland Laboratory, American Red Cross, Rockville, MD, USA. drohan@usa.redcross.org
authors.forename: W N
authors.initials: WN
authors.lastname: Drohan
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D019149:Bioreactors; D001798:Blood Proteins / Q000096:biosynthesis / Q000235:genetics*; D005544:Forecasting; D006801:Humans; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000096:biosynthesis
chemical_list: D001798:Blood Proteins; D011994:Recombinant Proteins